Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENT Extension
NCT02573467Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2015
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of bimagrumab in sporadic inclusion body myositis (sIBM) (4 arms), sponsored by Novartis. Primary endpoints: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths up to 14 months and Change From Core Study Baseline in 6 Minute Walking Distance Test. Started Nov 2015; status: completed.
02
Drugs
bimagrumab
03
Conditions
sporadic inclusion body myositis (sIBM)
Beyond the preview
Go deeper on NCT02573467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573467.